Erratum to: The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Josh J. Carlson · Joshua A. Roth

Published online: 8 June 2014
© Springer Science+Business Media New York 2014

Erratum to: Breast Cancer Res Treat (2013) 141:13–22 DOI 10.1007/s10549-013-2666-z

In the original publication of the article, a misstatement was found in the abstract section. The author apologizes for this error. The sentence which reads as, “High RS patients were

significantly more likely to follow the treatment suggested by ODX versus low RS patients RR: 1.07 (1.01–1.14)” should read as, “Low RS patients were significantly more likely to follow the treatment suggested by ODX versus high RS patients RR: 1.07 (1.01–1.14)”.

The online version of the original article can be found under doi:[10.1007/s10549-013-2666-z](https://doi.org/10.1007/s10549-013-2666-z).

J. J. Carlson (✉)
Pharmaceutical Outcomes Research and Policy Program,
University of Washington, 1959 NE Pacific Ave,
Box 357630, Seattle, WA 98195-7630, USA
e-mail: carlsojj@uw.edu

J. J. Carlson · J. A. Roth
Fred Hutchinson Cancer Research Center, Seattle, WA, USA

J. A. Roth
Group Health Research Institute, Seattle, WA, USA